{"id":71510,"date":"2026-05-20T10:35:00","date_gmt":"2026-05-20T10:35:00","guid":{"rendered":"https:\/\/medsbase.com\/b7-33\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"b7-33","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/b7-33\/","title":{"rendered":"B7-33 (An\u00e1logo da Cadeia B da Relaxina RXFP1 com Vi\u00e9s)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 B7-33?<\/h3>\n<p style=\"margin: 0;\"><strong>B7-33<\/strong> \u00e9 um an\u00e1logo sint\u00e9tico de 33 amino\u00e1cidos <strong>an\u00e1logo pept\u00eddico de cadeia \u00fanica da cadeia B da relaxina<\/strong> desenvolvido por Hossain, Howe e colegas no Instituto Florey (Melbourne, Austr\u00e1lia) e publicado na <em>Nature Communications<\/em> (2017). Enquanto a relaxina-2 nativa (o horm\u00f4nio can\u00f4nico para tratamento de fibrose, clinicamente Serelaxina) \u00e9 um pept\u00eddeo de duas cadeias ligadas por dissulfeto A\/B que ativa tanto RXFP1 (anti-fibr\u00f3tico) quanto RXFP2 (pr\u00f3-sobreviv\u00eancia de c\u00e9lulas cancerosas), B7-33 \u00e9 um <strong>agonista seletivo de RXFP1<\/strong> \u2014 single-chain B-only design that selectively engages RXFP1&#8217;s anti-fibrotic signalling (ERK1\/2 pathway \u2192 MMP-2 upregulation \u2192 ECM degradation) while avoiding RXFP1&#8217;s pro-cancer cAMP signalling that contributed to Serelaxin&#8217;s discontinuation. Published studies applications: heart failure, liver \/ kidney \/ lung \/ cardiac fibrosis, pre-eclampsia. <em>For clinical studies use only.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">An\u00e1logo sint\u00e9tico de cadeia \u00fanica da cadeia B da relaxina (33 aa); agonista seletivo do receptor RXFP1 (via anti-fibr\u00f3tica ERK, com sinaliza\u00e7\u00e3o reduzida de cAMP pr\u00f3-sobreviv\u00eancia)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">B7-33 (an\u00e1logo da cadeia B da relaxina 7-33 com modifica\u00e7\u00f5es estabilizadoras; Hossain et al. 2017 Nat Commun)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pharmaceutical-grade peptide \u2014 no widely-registered single CAS; identification by published sequence and supplier COA<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">An\u00e1logo de cadeia \u00fanica de 33 res\u00edduos da cadeia B \u2014 MF aproximado derivado da sequ\u00eancia C<sub>164<\/sub>H<sub>252<\/sub>N<sub>50<\/sub>O<sub>45<\/sub>S<sub>2<\/sub>; MW publicado ~3.728 Da (Hossain &amp; Bathgate 2015, J Med Chem).<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Comprimento da Sequ\u00eancia \/ MW<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">33 amino\u00e1cidos derivados da cadeia B da H2-relaxina com modifica\u00e7\u00f5es N- e C-terminais para solubilidade\/estabilidade; MW ~3.800 Da<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Agonista seletivo de RXFP1<\/strong>. Ativa seletivamente ERK1\/2 \u2192 upregula\u00e7\u00e3o de MMP-2\/MMP-9 \u2192 via de degrada\u00e7\u00e3o de col\u00e1geno\/remodela\u00e7\u00e3o da matriz extracelular (o bra\u00e7o anti-fibr\u00f3tico da sinaliza\u00e7\u00e3o do RXFP1) com redu\u00e7\u00e3o na ativa\u00e7\u00e3o da sinaliza\u00e7\u00e3o via cAMP do RXFP1 (a via implicada nos eventos card\u00edacos adversos do Serelaxina e no efeito pr\u00f3-sobreviv\u00eancia de c\u00e9lulas cancerosas que complicou o desenvolvimento cl\u00ednico da relaxina).<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Forma \/ Pureza \/ Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Para uso exclusivo em pesquisa laboratorial. N\u00e3o est\u00e1 na Lista de Subst\u00e2ncias Proibidas da WADA. Aviptadil (formula\u00e7\u00e3o sint\u00e9tica de VIP) teve pesquisa em Fase III por via inalat\u00f3ria para ARDS da COVID-19, mas n\u00e3o obteve aprova\u00e7\u00e3o regulat\u00f3ria.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Agonismo Seletivo de RXFP1 (ERK sem cAMP)<\/h2>\n<p>B7-33 was designed by the Hossain \/ Howe \/ Bathgate group at the Florey Institute as an answer to the &#8220;Serelaxin problem&#8221;. Serelaxin (recombinant human relaxin-2) had completed Phase III trials for acute heart failure but failed to gain FDA approval \u2014 partly because of mixed cardiovascular safety signals attributed to RXFP1&#8217;s dual signalling (anti-fibrotic ERK pathway helpful; cAMP pathway potentially pro-arrhythmic and pro-cancer-cell-survival). B7-33&#8217;s design hypothesis: the relaxin <strong>apenas a cadeia B<\/strong> (a cadeia que media a liga\u00e7\u00e3o ao RXFP1) pode ser projetada em um pept\u00eddeo est\u00e1vel de cadeia \u00fanica que ativa apenas o bra\u00e7o anti-fibr\u00f3tico da sinaliza\u00e7\u00e3o do RXFP1 via ERK1\/2 \/ upregula\u00e7\u00e3o de MMP, evitando o bra\u00e7o pr\u00f3-c\u00e2ncer\/pr\u00f3-arritmia mediado por cAMP. O artigo publicado na Nature Communications em 2017 confirmou isso: o B7-33 produz ativa\u00e7\u00e3o mensur\u00e1vel de RXFP1-ERK1\/2, mas eleva\u00e7\u00e3o m\u00ednima de cAMP \u2014 definido como agonismo enviesado. Em modelos publicados de fibrose card\u00edaca, fibrose renal e pr\u00e9-ecl\u00e2mpsia em camundongos, o B7-33 produziu efic\u00e1cia anti-fibr\u00f3tica equivalente ou superior \u00e0 relaxina nativa, sem as complica\u00e7\u00f5es mediadas por cAMP. <\/p>\n<h2>Published Evidence<\/h2>\n<ul>\n<li><strong>Farmacologia de agonista enviesado do RXFP1<\/strong> \u2014 exemplo can\u00f4nico de enviesamento de via de receptor na literatura publicada sobre engenharia de pept\u00eddeos<\/li>\n<li><strong>Cardiac fibrosis studies<\/strong> \u2014 modelos de cardiomiopatia isqu\u00eamica e hipertensiva; leituras de deposi\u00e7\u00e3o de col\u00e1geno e remodela\u00e7\u00e3o da MEC<\/li>\n<li><strong>Kidney \/ liver \/ lung fibrosis studies<\/strong> \u2014 upregula\u00e7\u00e3o de MMP-2\/9 e degrada\u00e7\u00e3o da MEC em modelos cr\u00f4nicos de fibrose<\/li>\n<li><strong>Pre-eclampsia studies<\/strong> \u2014 publicado em modelos de camundongos gr\u00e1vidas; o eixo da relaxina est\u00e1 centralmente envolvido na adapta\u00e7\u00e3o hemodin\u00e2mica da gravidez normal<\/li>\n<li><strong>Heart failure preclinical studies<\/strong> \u2014 alternative to Serelaxin for clinical-translational studies where the biased-signalling profile is more favourable<\/li>\n<li><strong>Acute kidney injury studies<\/strong> \u2014 estudos de prote\u00e7\u00e3o tubular renal mediada por RXFP1<\/li>\n<\/ul>\n<p>For broader context see related peptides: <a href=\"https:\/\/medsbase.com\/pt-br\/bpc-157\/\">BPC-157<\/a> (reparo tecidual), <a href=\"https:\/\/medsbase.com\/pt-br\/tb-500\/\">TB-500<\/a> (recupera\u00e7\u00e3o), <a href=\"https:\/\/medsbase.com\/pt-br\/ghk-cu\/\">GHK-Cu<\/a> (remodela\u00e7\u00e3o da pele e tecido conjuntivo). Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">cat\u00e1logo de pept\u00eddeos<\/a>. <\/p>\n<h2>Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong> \u2014 protocol standard for in-vitro RXFP1 pharmacology and short-cycle in-vivo work<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong> \u2014 modelos de fibrose com dosagem cr\u00f4nica estendida, tamanhos de amostra multicohorte; menor custo por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com nosso <a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, preservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p>Liofilizado 2\u20138 \u00b0C a curto prazo, \u221220 \u00b0C a longo prazo. Reconstituir com \u00e1gua bacteriost\u00e1tica (1,0 mL por frasco de 2 mg \u2192 2 mg\/mL; 1,0 mL por frasco de 10 mg \u2192 10 mg\/mL). Evitar ciclos de congelamento-descongelamento. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>Como o B7-33 \u00e9 diferente do Serelaxina \/ relaxina-2 nativa?<\/h3>\n<p>A relaxina-2 nativa \u00e9 um pept\u00eddeo de duas cadeias (A + B) ligadas por dissulfeto que ativa ambas as vias a jusante do RXFP1 \u2014 o bra\u00e7o anti-fibr\u00f3tico ERK e o bra\u00e7o pr\u00f3-sobreviv\u00eancia cAMP. O Serelaxina \u00e9 a relaxina-2 nativa recombinante; ele falhou na Fase III para insufici\u00eancia card\u00edaca aguda em parte devido a sinais adversos da via cAMP. O B7-33 \u00e9 um an\u00e1logo de cadeia \u00fanica B que engaja seletivamente o bra\u00e7o anti-fibr\u00f3tico ERK sem o sinal da via cAMP. <\/p>\n<h3>O B7-33 j\u00e1 esteve em ensaios cl\u00ednicos?<\/h3>\n<p>B7-33 remains a preclinical studies compound; no formal Phase I\/II human clinical trials have been completed to date. <\/p>\n<h3>What dose ranges are used in studies?<\/h3>\n<p>Protocolos publicados em modelos murinos in vivo utilizam 25\u201350 \u00b5g\/kg por via subcut\u00e2nea diariamente por 2\u20134 semanas. Trabalhos in vitro com culturas celulares utilizam concentra\u00e7\u00f5es nanomolares. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Tissue-Repair \/ Anti-Fibrotic Peptides<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Pentadecapeptide tissue-repair compound<\/li>\n<li><a href=\"\/pt-br\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Fragmento de Timosina Beta-4, recupera\u00e7\u00e3o<\/li>\n<li><a href=\"\/pt-br\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Tripept\u00eddeo ligante de cobre, remodela\u00e7\u00e3o da pele\/tecido conjuntivo<\/li>\n<li><a href=\"\/pt-br\/glow-blend\/\"><strong>GLOW Blend<\/strong><\/a> \u2014 Combina\u00e7\u00e3o BPC-157 + GHK-Cu + TB-500<\/li>\n<li><a href=\"\/pt-br\/peptide-healing-stack-bpc-157-tb-500-bac-water\/\"><strong>Kit de Recupera\u00e7\u00e3o com Pept\u00eddeos<\/strong><\/a> \u2014 Pacote BPC-157 + TB-500<\/li>\n<li><a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, preservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 An\u00e1logo sint\u00e9tico de cadeia \u00fanica de relaxina-B de 33-aa<br \/>\n\u2705 Agonista enviesado de RXFP1 \u2014 anti-fibr\u00f3tico ERK1\/2 sem sinaliza\u00e7\u00e3o pr\u00f3-c\u00e2ncer via cAMP<br \/>\n\u2705 Hossain\/Howe (Instituto Florey) 2017 Nat Commun: vers\u00e3o modificada de Serelaxina<br \/>\n\u2705 Cardiac\/kidney\/liver\/lung fibrosis studies; pre-eclampsia models<br \/>\n\u2705 ~PM 3.800 Da; dosagem publicada 25-50 \u00b5g\/kg\/dia SC em camundongos<\/p>\n<p><strong>B7-33<\/strong> contains synthetic 33-aa relaxin-B-chain analogue peptide.<\/p>","protected":false},"featured_media":71533,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6562,6559,6563,6560,6494,6561],"class_list":["post-71510","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-anti-fibrotic-peptide","product_tag-b7-33","product_tag-cardiac-fibrosis-research","product_tag-relaxin-analogue","product_tag-research-peptide","product_tag-rxfp1-biased-agonist","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/71510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=71510"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/71533"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=71510"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=71510"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=71510"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=71510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}